We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-11.17%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$775M
AUM Growth
-$224M
Cap. Flow
-$90.9M
Cap. Flow %
-11.73%
Top 10 Hldgs %
46.3%
Holding
85
New
17
Increased
18
Reduced
18
Closed
20

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$27M
2
OSUR icon
OraSure Technologies
OSUR
+$24.4M
3
ILMN icon
Illumina
ILMN
+$21.6M
4
ACLX
Arcellx
ACLX
+$16.5M
5
HOLX
Hologic
HOLX
+$16.2M

Top Sells

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$59.5M
2
AZN icon
AstraZeneca
AZN
+$21.9M
3
CCCC icon
C4 Therapeutics
CCCC
+$9.58M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$7.53M
5
SNN icon
Smith & Nephew
SNN
+$6.99M

Sector Composition

Rank Sector Weight
1 Healthcare 80.09%
2 Financials 0.5%
3 Consumer Staples 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNN icon
26
Smith & Nephew
SNN
$12.4B
$12.3M 1.58%
385,000
-208,200
-35% -$6.99M
STE icon
27
Steris
STE
$22.5B
$9.97M 1.29%
41,260
-10,840
-21% -$2.51M
LNTH icon
28
Lantheus
LNTH
$6.59B
$9.87M 1.27%
178,427
-1,586,200
-90% -$59.5M
CVS icon
29
CVS Health
CVS
$124B
$9.36M 1.21%
92,500
-45,500
-33% -$4.78M
SUPN icon
30
Supernus Pharmaceuticals
SUPN
$2.76B
$8.11M 1.05%
+251,000
New +$7.7M
TXG icon
31
10x Genomics
TXG
$5.77B
$8.07M 1.04%
+106,139
New +$9.29M
FATE icon
32
Fate Therapeutics
FATE
$287M
$7.98M 1.03%
205,900
+198,100
+2,540% +$7.67M
PCVX icon
33
Vaxcyte
PCVX
$8.38B
$7.93M 1.02%
328,350
+33,600
+11% +$734K
MIRM icon
34
Mirum Pharmaceuticals
MIRM
$5.81B
$7.56M 0.98%
+343,500
New +$7.01M
AZN icon
35
AstraZeneca
AZN
$249B
$7.48M 0.96%
56,348
-182,950
-76% -$21.9M
EIGR
36
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$6.5M 0.84%
+26,100
New +$4.13M
NTRA icon
37
Natera
NTRA
$38.1B
$6.3M 0.81%
155,000
-72,599
-32% -$4.36M
DXCM icon
38
DexCom
DXCM
$31.4B
$5.94M 0.77%
46,436
+15,400
+50% +$1.68M
XENE icon
39
Xenon Pharmaceuticals
XENE
$6.2B
$5.8M 0.75%
189,797
-189,200
-50% -$5.66M
CVRX icon
40
CVRx
CVRX
$156M
$5.76M 0.74%
962,165
– –
NEO icon
41
NeoGenomics
NEO
$2B
$5.59M 0.72%
+460,000
New +$9.68M
INMD icon
42
InMode
INMD
$867M
$5.41M 0.7%
+146,500
New +$6.56M
CCCC icon
43
C4 Therapeutics
CCCC
$400M
$4.04M 0.52%
166,736
-394,386
-70% -$9.58M
SKIN icon
44
SkinHealth Systems
SKIN
$96.4M
$3.84M 0.5%
+227,612
New +$3.76M
SIEN
45
DELISTED
Sientra, Inc.
SIEN
$3.64M 0.47%
164,134
-25,054
-13% -$686K
IOBT
46
DELISTED
IO Biotech
IOBT
$3.56M 0.46%
672,734
– –
XLO icon
47
Xilio Therapeutics
XLO
$62.4M
$3.38M 0.44%
34,107
– –
ARYD
48
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$2.94M 0.38%
300,000
– –
YMAB
49
DELISTED
Y-mAbs Therapeutics
YMAB
$2.84M 0.37%
238,982
-71,512
-23% -$734K
IMUX icon
50
Immunic
IMUX
$193M
$2.71M 0.35%
24,000
+6,500
+37% +$752K
1
2
3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Soleus Capital Management held 85 positions worth $775M, down 22% from $999M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Soleus Capital Management withdrew a net $90.9M in Q1 2022, closing 20 positions and reducing 18 holdings. Its most notable exit was Bioventus, an estimated $6.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 71% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in OraSure Technologies worth $20.7M.

  • Soleus Capital Management's largest Q1 2022 buy was OraSure Technologies: 3,055,193 shares worth $20.7M.
  • Soleus Capital Management added most to United Therapeutics in Q1 2022, an estimated $27M increase.
  • Soleus Capital Management's biggest Q1 2022 reduction was Lantheus, cutting an estimated $59.5M.
  • Soleus Capital Management fully exited Bioventus in Q1 2022, selling an estimated $6.21M.
  • Soleus Capital Management's ten largest holdings make up 46% of its $775M portfolio in Q1 2022.
  • Soleus Capital Management opened 17 new positions and closed 20 in Q1 2022.
  • Soleus Capital Management's portfolio value fell 22% quarter-over-quarter to $775M.

Based on Soleus Capital Management's 13F filing for Q1 2022, filed 16 May 2022.